Published in J Pharmacol Exp Ther on March 01, 1976
Comparison of the CNS effects induced by TRH and bicuculline after microinjection into medial septum, substantia nigra and inferior colliculus: absence of support for a GABA antagonist action for TRH. Pharmacol Biochem Behav (1984) 0.92
Site-specific enhancement of gamma-aminobutyric acid-mediated inhibition of neural activity by ethanol in the rat medial septal area. J Pharmacol Exp Ther (1990) 0.91
Interactions between TRH and ethanol in the medial septum. Pharmacol Biochem Behav (1986) 0.80
Mechanistic and functional divergence between thyrotropin-releasing hormone and RO 15-4513 interactions with ethanol. Alcohol Clin Exp Res (1989) 0.75
Prolactin and thyrotropin release in man by synthetic pyroglutamyl-histidyl-prolinamide. Biochem Biophys Res Commun (1971) 2.07
Thyrotropin-releasing hormone: regional distribution in rat brain. Science (1974) 1.45
Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone. Science (1972) 1.31
Comparative pharmacodynamics of sympathomimetic imidazolines; studies on intestinal smooth muscle of the rabbit and the cardiovascular system of the cat. Arch Int Pharmacodyn Ther (1965) 1.24
Thyrotropin-releasing hormone (TRH): distribution in hypothalamic and extrahypothalamic brain tissues of mammalian and submammalian chordates. Endocrinology (1974) 1.03
Thyrotropin releasing hormine (TRH): distribution in the brain, blood and urine of the rat. Life Sci (1974) 0.98
Effects of thyrotropin-releasing hormone (TRH) on the actions of pentobarbital and other centrally acting drugs. J Pharmacol Exp Ther (1975) 0.97
Thydrotropin releasing hormone: antagonism of pentobarbital in rodents. Life Sci (1974) 0.91
Enhancement of cerebral noradrenaline turnover by thyrotropin-releasing hormone. Nature (1974) 0.90
In vitro plasma inactivation of thyrotropin releasing factor (TRF) and related peptides. Its inhibition by various means and by the synthetic dipeptide PCA-His-OME. Hormones (1971) 0.90
Site of inactivation of thyrotropin-releasing hormone by human plasma. Biochemistry (1971) 0.90
Antagonism of ethanol narcosis by thyrotropin releasing hormone. Life Sci (1974) 0.87
Effects of ethanol and pentobarbital on release of acetylcholine from cerebral cortex slices. J Pharmacol Exp Ther (1967) 0.87
Alteration of cortical and reticular acetylcholine release by ethanol in vivo. J Pharmacol Exp Ther (1973) 0.87
Norepinephrine metabolism in the rat brain following acute and chronic administration of thyrotropin releasing hormone. Psychopharmacologia (1974) 0.81
Factors in blood influencing the determination of thyrotropin releasing hormone. Clin Chim Acta (1973) 0.81
Chemistry of the hypothalamic releasing factors--studies on structure-function relationships. Front Neuroendocrinol (1973) 0.81
The pharmacology fo gross behavioural effects of cholinomimetic substances injected into the cerebral ventricles of unanaesthetized cats: evidence for central muscarinic mediation. Neuropharmacology (1974) 0.80
Immunoreactive thyrotrophin releasing factor in gastropod circumoesophageal ganglia. Nature (1975) 0.80
A possible mechanism for the anti-depressant activity of thyrotropin releasing hormone. Life Sci (1974) 0.80
The effects of chlorpromazine and ethanol on in vivo release of acetylcholine from the cerebral cortex. Comp Gen Pharmacol (1971) 0.79
Enhancement of cerebral noradrenaline turnover by thyrotropin-releasing hormone: evidence by fluorescence histochemistry. Experientia (1974) 0.78
An analysis of the gross behavioural changes induced by tetraethylammonium and a comparison with other substances affecting the autonomic and central nervous system after inraventricular inejctions to conscious cats. Neuropharmacology (1974) 0.78
The role of TRH in the neoteny of the Mexican axolotl (Ambystoma mexicanum). Gen Comp Endocrinol (1974) 0.78
Parameters of alteration of pentobarbital response by hypothalamic polypeptides. Neuropsychobiology (1975) 0.78
Biosynthesis of thyrotropin releasing factor by newt (Triturus viridescens) brain in vitro. Isolation and characterization of thyrotropin releasing factor. J Neurochem (1974) 0.77
Effect of ethanol on cyclic AMP levels in the rat brain. Life Sci (1973) 0.77
Behavior modification with culturally deprived school children: two case studies. J Appl Behav Anal (1969) 3.55
Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res (1996) 3.03
Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med (1999) 2.72
Induction of maternal behavior in virgin rats after intracerebroventricular administration of oxytocin. Proc Natl Acad Sci U S A (1979) 2.43
Oxytocin induces maternal behavior in virgin female rats. Science (1982) 2.23
Selective release of newly synthesized norepinephrine from the cat spleen during sympathetic nerve stimulation. J Pharmacol Exp Ther (1968) 1.99
Metabolism of normetanephrine-H3 in rat brain--identification of conjugated 3-methoxy-4-hydrophenylglycol as the major metabolite. Biochem Pharmacol (1968) 1.86
Subclinical hypothyroidism: a modifiable risk factor for depression? Am J Psychiatry (1993) 1.78
Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. J Pharmacol Exp Ther (1970) 1.69
3-methoxy-4-hydroxyphenylglycol sulfate in brain and cerebrospinal fluid. Biochem Pharmacol (1968) 1.64
Multiple opiate receptors: different regional distribution in the brain and differential binding of opiates and opioid peptides. Mol Pharmacol (1979) 1.59
A hypothesis of thyroid-catecholamine-receptor interaction. Its relevance to affective illness. Arch Gen Psychiatry (1981) 1.49
Microcolumn separations and the analysis of single cells. Science (1989) 1.47
Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc Natl Acad Sci U S A (1991) 1.38
Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther (1983) 1.36
Metabolism of tyramine-3H and octopamine-3H by rat brain. Biochem Pharmacol (1969) 1.35
Effects of thyrotropin-releasing hormone in depression. Lancet (1972) 1.34
Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci U S A (1996) 1.32
Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br J Pharmacol (1971) 1.31
Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone. Science (1972) 1.31
Multiple withdrawals from chronic ethanol "kindles" inferior collicular seizure activity: evidence for kindling of seizures associated with alcoholism. Alcohol Clin Exp Res (1990) 1.30
Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature (1976) 1.29
Induction of Fos-like proteins and ultrasonic vocalizations during ethanol withdrawal: further evidence for withdrawal-induced anxiety. Alcohol Clin Exp Res (1998) 1.28
Effects of acute and chronic 1,3-butanediol treatment on central nervous system function: a comparison with ethanol. J Pharmacol Exp Ther (1981) 1.26
Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety. Brain Res (1996) 1.24
Mental changes accompanying thyroid gland dysfunction. A reappraisal using objective psychological measurement. Arch Gen Psychiatry (1969) 1.24
Flumazenil blockade of anxiety following ethanol withdrawal in rats. Psychopharmacology (Berl) (1997) 1.24
Abnormalities of indoleamines in affective disorders. Arch Gen Psychiatry (1972) 1.20
Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther (1987) 1.19
Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry (1982) 1.19
Sensitivity to ethanol across development in rats: comparison to [3H]zolpidem binding. Alcohol Clin Exp Res (1998) 1.17
Effect of central catecholamine alterations on the hypothermic response to 6-hydroxydopamine in desipramine treated rats. Br J Pharmacol (1971) 1.17
Characterization of susceptibility to audiogenic seizures in ethanol-dependent rats after microinjection of gamma-aminobutyric acid (GABA) agonists into the inferior colliculus, substantia nigra or medial septum. J Pharmacol Exp Ther (1983) 1.17
Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. J Neurosci (1993) 1.16
Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther (1993) 1.16
Differential sensitivity of ethanol withdrawal signs in the rat to gamma-aminobutyric acid (GABA)mimetics: blockade of audiogenic seizures but not forelimb tremors. J Pharmacol Exp Ther (1983) 1.14
Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: effects of 6-hydroxydopamine. Br J Pharmacol (1972) 1.14
Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients: a review. Am J Psychiatry (1982) 1.13
Oxytocin facilitates the sexual receptivity of estrogen-treated female rats. Neuropeptides (1986) 1.12
Comparison of tyrosine hydroxylase and dopamine-beta-hydroxylase inhibition with the effects of various 6-hydroxydopamine treatments on d-amphetamine induced motor activity. Psychopharmacologia (1974) 1.10
Growth and behavioral changes in developing rats treated intracisternally with 6-hydroxydopamine: evidence for involvement of brain dopamine. J Pharmacol Exp Ther (1973) 1.09
Borderline hypothyroidism and depression. Annu Rev Med (1995) 1.08
Enhanced ultrasonic vocalization and Fos protein expression following ethanol withdrawal: effects of flumazenil. Psychopharmacology (Berl) (2000) 1.08
Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther (1984) 1.07
Evaluation of certain food additives and contaminants. World Health Organ Tech Rep Ser (2007) 1.06
Enkephalin action on the mesolimbic system: a dopamine-dependent and a dopamine-independent increase in locomotor activity. J Pharmacol Exp Ther (1983) 1.05
Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry (1969) 1.04
Multiple attempts at embryo transfer: does this affect in-vitro fertilization treatment outcome? Hum Reprod (1997) 1.03
Self-injurious behavior: gene-brain-behavior relationships. Ment Retard Dev Disabil Res Rev (2001) 1.03
Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther (1980) 1.02
Neurotensin blocks certain amphetamine-induced behaviours. Nature (1981) 1.02
Oxytocin antiserum delays onset of ovarian steroid-induced maternal behavior. Neuropeptides (1985) 1.01
Preparative methods for brain slices: a discussion. J Neurosci Methods (1995) 1.01
Neurotensin: central nervous system effects of a hypothalamic peptide. Brain Res (1977) 1.01
6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J Pharmacol Exp Ther (1987) 1.01
Regional specificity of ethanol and NMDA action in brain revealed with FOS-like immunohistochemistry and differential routes of drug administration. Alcohol Clin Exp Res (2001) 1.01
Ontogeny of D1A and D2 dopamine receptor subtypes in rat brain using in situ hybridization and receptor binding. Neuroscience (1994) 1.01
The neuroradiographic diagnosis of lumbar herniated nucleus pulposus: II. A comparison of computed tomography (CT), myelography, CT-myelography, and magnetic resonance imaging. Spine (Phila Pa 1976) (1989) 1.01
8-Amino-3-benzyl-1,2,4-triazolo[4,3-a]pyrazines. Synthesis and anticonvulsant activity. J Med Chem (1995) 1.00
Influence of age and strain on striatal dopamine loss in a genetic mouse model of Lesch-Nyhan disease. J Neurochem (1999) 1.00
Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci (1996) 0.99
A survey study of neuropsychiatric complaints in patients with Graves' disease. J Neuropsychiatry Clin Neurosci (1996) 0.99
Neurotensin, a biologically active peptide. Life Sci (1978) 0.99
Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine. Proc Natl Acad Sci U S A (1979) 0.98
GABAergic modulation of ethanol-induced motor impairment. J Pharmacol Exp Ther (1982) 0.98
Supersensitivity to the respiratory stimulatory effect of TRH in 5,7-dihydroxytryptamine-treated rats. Brain Res (1984) 0.97
Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res (1998) 0.97
Effects of thyrotropin-releasing hormone (TRH) on the actions of pentobarbital and other centrally acting drugs. J Pharmacol Exp Ther (1975) 0.97
Clinical studies of methylphenidate serum levels in children and adults. J Am Acad Child Psychiatry (1982) 0.96
Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res (1997) 0.96
The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry (1972) 0.96
Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. Neuroscience (1983) 0.96
Stimulant action of thyrotropin releasing hormone on cat spinal cord. Neuropharmacology (1978) 0.95
Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. J Pharmacol Exp Ther (1996) 0.95
Simultaneous quantification of dopamine, 5-hydroxytryptamine and four metabolically related compounds by means of reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr (1981) 0.95
The effect of neurotensin on food consumption in the rat. Eur J Pharmacol (1982) 0.95
Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem (1981) 0.94
Oxytocin and vasopressin immunoreactivity in hypothalamic and extrahypothalamic sites in late pregnant and postpartum rats. Neuroendocrinology (1987) 0.94
Studies of bupropion's mechanism of antidepressant activity. J Clin Psychiatry (1983) 0.93
PNA-dependent gene chemistry: stable coupling of peptides and oligonucleotides to plasmid DNA. Biotechniques (2000) 0.93
The neuropharmacology of respiratory control. Pharmacol Rev (1982) 0.93
Dietary supplements and natural products as psychotherapeutic agents. Psychosom Med (1999) 0.92
Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. Neuroscience (1984) 0.92
Evidence for involvement of 5-hydroxytryptamine in the actions of amphetamine. Br J Pharmacol (1974) 0.92
Comparison of the CNS effects induced by TRH and bicuculline after microinjection into medial septum, substantia nigra and inferior colliculus: absence of support for a GABA antagonist action for TRH. Pharmacol Biochem Behav (1984) 0.92
Metabolism of some phenylethylamines and their beta-hydroxylated analogs in brain. J Pharmacol Exp Ther (1969) 0.92
Serotonin release from brain slices by electrical stimulation: regional differences and effect of LSD. Science (1967) 0.92
Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity. J Pharmacol Exp Ther (1979) 0.92
Alteration of avoidance and ingestive behavior after destruction of central catecholamine pathways with 6-hydroxydopamine. Pharmacol Biochem Behav (1975) 0.92
L-tryptophan in mania. Contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry (1974) 0.92
Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment. Am J Psychiatry (1982) 0.92
Molecular basis for regionally specific action of ethanol on gamma-aminobutyric acidA receptors: generalization to other ligand-gated ion channels. J Pharmacol Exp Ther (1993) 0.92